TXG 10x Genomics, Inc.
TXG 10x Genomics, Inc.
Healthcare · Health Information Services
Desk view
Market read
POC $21.29 · VWAP $35.69 · +95.8% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, CFO + 4 others sold $4.8M, Aug 13–26
Coverage
2 watchlists
TXG Price Structure
Loading timeframes…
Peers
Every watchlist TXG belongs to, members best 30-day change first — TXG highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
Decision history
2 scored calls · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-06-30: revenue $151M, diluted EPS -$0.14, net income -$18M (SEC filing). Across the print the stock moved +9.6% (close before → first close after).
full note →Against street estimates
How TXG's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about TXG from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 11 days ago · Oct 6
- Latest News about 10x Genomics, Inc. - Common Stock (Nasdaq:TXG) | 10x Genomics, Inc. - Common Stock (Nasdaq:TXG) News
- TXG Stock Price (-17.08) | Stock Quote, Chart & News for 10x Genomics on Fox Business
- 10x Genomics Stock Price | TXG Stock Quote, News, and History | Markets Insider
- Investor Relations - 10x Genomics
- 10x Genomics Reports Second Quarter 2026 Financial Results – Company Announcement - FT.com
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
TXG research tape
60 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to TXG.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet